Research
Zanamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments
BMJ 2014; 348 doi: https://doi.org/10.1136/bmj.g2547 (Published 09 April 2014) Cite this as: BMJ 2014;348:g2547
Data supplement
Web Extra
Extra material supplied by the author
Files in this Data Supplement:
- Data Supplement - Appendix 1: Search methods for identification of clinical study reports of zanamivir
- Data Supplement - Appendix 2: Searches for regulatory information
- Data Supplement - Appendix 3: List of prespecified outcomes and protocol amendments in zanamivir treatment trials
- Data Supplement - Appendix 4: List of protocol amendments in zanamivir prophylaxis trials
- Data Supplement - Appendix 5: Reference list of included zanamivir trials
- Data Supplement - Appendix 6: Explanations of other biases relating to zanamivir by trial identifier
- Data Supplement - Appendix 7: Forest plots for main results
- Data Supplement - Appendix 8: Cochrane A159 NI peer review history
Related articles
- Editorial Published: 09 April 2014; BMJ 348 doi:10.1136/bmj.g2548
- Research Published: 09 April 2014; BMJ 348 doi:10.1136/bmj.g2545
- Research Published: 08 December 2009; BMJ 339 doi:10.1136/bmj.b5106
- Editorial Published: 11 September 1999; BMJ 319 doi:10.1136/bmj.319.7211.655
- Paper Published: 05 June 2003; BMJ 326 doi:10.1136/bmj.326.7401.1235
- Research Published: 10 August 2009; BMJ 339 doi:10.1136/bmj.b3172
- News Published: 10 April 2014; BMJ 348 doi:10.1136/bmj.g2675
- Editor's Choice Published: 10 April 2014; BMJ 348 doi:10.1136/bmj.g2695
- Analysis Published: 10 April 2014; BMJ 348 doi:10.1136/bmj.g2263
- Editorial Published: 28 May 2014; BMJ 348 doi:10.1136/bmj.g3561
See more
- Marburg virus: First cases in Rwanda spark international alarmBMJ October 02, 2024, 387 q2155; DOI: https://doi.org/10.1136/bmj.q2155
- Mpox is accelerating antimicrobial resistance in Africa, officials warnBMJ September 27, 2024, 386 q2124; DOI: https://doi.org/10.1136/bmj.q2124
- Politicians are failing to prepare for next pandemic, warns head of European health agencyBMJ September 26, 2024, 386 q2115; DOI: https://doi.org/10.1136/bmj.q2115
- Whooping cough: Fivefold rise in US cases spells return to pre-pandemic levelsBMJ September 26, 2024, 386 q2114; DOI: https://doi.org/10.1136/bmj.q2114
- Boy who survived life support withdrawal confirms “medicine is a science of uncertainty,” says judgeBMJ September 26, 2024, 386 q2108; DOI: https://doi.org/10.1136/bmj.q2108
Cited by...
- Clinical study reports published by the European Medicines Agency 2016-2018: a cross-sectional analysis
- Prescription of anti-influenza drugs in Japan, 2014-2020: a retrospective study using open data from the national claims database
- New Perspectives on Antimicrobial Agents: Remdesivir Treatment for COVID-19
- Antiviral medications for influenza
- Zanamivir for influenza in adults and children shows limited benefit for treatment of symptomatic influenza and no effect on relevant complications
- Was the flu drug zanamivir a breakthrough or money for old rope?
- Redacted policy on sharing drug trial data in Europe
- Neuraminidase inhibitors for influenza
- Cochrane review questions effectiveness of neuraminidase inhibitors
- Tug of war for antiviral drugs data
- The Tamiflu trials